Advertisement
Codiak BioSciences Inc. (CDAK)
Codiak BioSciences Statistics
Share Statistics
Codiak BioSciences has 0 shares outstanding. The number of shares has increased by 34.75% in one year.
| Shares Outstanding | 0 |
| Shares Change (YoY) | 34.75% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 19.63M |
| Failed to Deliver (FTD) Shares | 19.5K |
| FTD / Avg. Volume | 1.22% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -5.83 and the forward PE ratio is null. Codiak BioSciences's PEG ratio is 0.07.
| PE Ratio | -5.83 |
| Forward PE | n/a |
| PS Ratio | 10.59 |
| Forward PS | n/a |
| PB Ratio | 4.54 |
| P/FCF Ratio | -3.14 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Codiak BioSciences has an Enterprise Value (EV) of 228.83M.
| EV / Sales | 9.98 |
| EV / EBITDA | -3.73 |
| EV / EBIT | -3.09 |
| EV / FCF | -2.96 |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 1.18.
| Current Ratio | 3.32 |
| Quick Ratio | 3.32 |
| Debt / Equity | 1.18 |
| Debt / EBITDA | -1.03 |
| Debt / FCF | -0.81 |
| Interest Coverage | -25.8 |
Financial Efficiency
Return on Equity is -77.81% and Return on Invested Capital is -66.9%.
| Return on Equity | -77.81% |
| Return on Assets | -24.25% |
| Return on Invested Capital | -66.9% |
| Revenue Per Employee | $224.85K |
| Profits Per Employee | $-408.17K |
| Employee Count | 102 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4.48M |
| Effective Tax Rate | -12.05% |
Stock Price Statistics
The stock price has increased by 200% in the last 52 weeks. The beta is 3.93, so Codiak BioSciences's price volatility has been higher than the market average.
| Beta | 3.93 |
| 52-Week Price Change | 200% |
| 50-Day Moving Average | 0.12 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 35.08 |
| Average Volume (20 Days) | 1.6M |
Income Statement
In the last 12 months, Codiak BioSciences had revenue of 22.93M and earned -41.63M in profits. Earnings per share was -1.91.
| Revenue | 22.93M |
| Gross Profit | 22.93M |
| Operating Income | -69.55M |
| Net Income | -41.63M |
| EBITDA | -61.33M |
| EBIT | -34.46M |
| Earnings Per Share (EPS) | -1.91 |
Balance Sheet
The company has 76.94M in cash and 62.98M in debt, giving a net cash position of 13.96M.
| Cash & Cash Equivalents | 76.94M |
| Total Debt | 62.98M |
| Net Cash | 13.96M |
| Retained Earnings | -325.25M |
| Total Assets | 134.4M |
| Working Capital | 46.78M |
Cash Flow
In the last 12 months, operating cash flow was -74.14M and capital expenditures -3.25M, giving a free cash flow of -77.39M.
| Operating Cash Flow | -74.14M |
| Capital Expenditures | -3.25M |
| Free Cash Flow | -77.39M |
| FCF Per Share | -3.55 |
Margins
Gross margin is 100%, with operating and profit margins of -303.24% and -181.53%.
| Gross Margin | 100% |
| Operating Margin | -303.24% |
| Pretax Margin | -162.01% |
| Profit Margin | -181.53% |
| EBITDA Margin | -267.39% |
| EBIT Margin | -303.24% |
| FCF Margin | -337.43% |
Dividends & Yields
CDAK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -17.15% |
| FCF Yield | -31.87% |
Analyst Forecast
Currently there are no analyst rating for CDAK.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -4.37 |
| Piotroski F-Score | 2 |